SE0301922D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0301922D0
SE0301922D0 SE0301922A SE0301922A SE0301922D0 SE 0301922 D0 SE0301922 D0 SE 0301922D0 SE 0301922 A SE0301922 A SE 0301922A SE 0301922 A SE0301922 A SE 0301922A SE 0301922 D0 SE0301922 D0 SE 0301922D0
Authority
SE
Sweden
Prior art keywords
alkyl
ring
aryl
heteroaryl
heterocycloalkyl
Prior art date
Application number
SE0301922A
Other languages
English (en)
Swedish (sv)
Inventor
Raymond Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0301922(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301922A priority Critical patent/SE0301922D0/xx
Publication of SE0301922D0 publication Critical patent/SE0301922D0/xx
Priority to US10/561,747 priority patent/US7485644B2/en
Priority to AT04743053T priority patent/ATE414063T1/de
Priority to HR20090009T priority patent/HRP20090009T3/xx
Priority to CN2004800182447A priority patent/CN1812974B/zh
Priority to NZ544208A priority patent/NZ544208A/en
Priority to EP04743053A priority patent/EP1644340B1/en
Priority to PT04743053T priority patent/PT1644340E/pt
Priority to DE602004017733T priority patent/DE602004017733D1/de
Priority to ES04743053T priority patent/ES2315675T3/es
Priority to CN201110103041XA priority patent/CN102229589A/zh
Priority to UAA200511723A priority patent/UA81491C2/uk
Priority to PL04743053T priority patent/PL1644340T3/pl
Priority to RU2005141058/04A priority patent/RU2351595C2/ru
Priority to MXPA05013460A priority patent/MXPA05013460A/es
Priority to JP2006516467A priority patent/JP4701167B2/ja
Priority to SI200430979T priority patent/SI1644340T1/sl
Priority to CA002529468A priority patent/CA2529468A1/en
Priority to BRPI0411929-0A priority patent/BRPI0411929A/pt
Priority to HK06106939.5A priority patent/HK1086835B/en
Priority to KR1020057024709A priority patent/KR20060026440A/ko
Priority to DK04743053T priority patent/DK1644340T3/da
Priority to PCT/GB2004/002702 priority patent/WO2005000822A1/en
Priority to AU2004251104A priority patent/AU2004251104B2/en
Priority to ARP040102258A priority patent/AR044931A1/es
Priority to MYPI20042517A priority patent/MY138680A/en
Priority to UY28387A priority patent/UY28387A1/es
Priority to TW093118692A priority patent/TW200524898A/zh
Priority to SA04250224A priority patent/SA04250224B1/ar
Priority to IL172615A priority patent/IL172615A0/en
Priority to ZA200510458A priority patent/ZA200510458B/xx
Priority to CO05130352A priority patent/CO5650254A2/es
Priority to IS8257A priority patent/IS8257A/is
Priority to NO20060444A priority patent/NO20060444L/no
Priority to CY20091100064T priority patent/CY1108757T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0301922A 2003-06-27 2003-06-27 Novel compounds SE0301922D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors
AU2004251104A AU2004251104B2 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors
JP2006516467A JP4701167B2 (ja) 2003-06-27 2004-06-23 メタロプロテイナーゼ阻害剤としてのｎ−｛（４−置換ピペラジン−１−スルホニルメチル）アルキル｝−ｎ−ヒドロキシホルムアミド化合物
BRPI0411929-0A BRPI0411929A (pt) 2003-06-27 2004-06-23 compostos de piperazino-(1-sulfonilmetil-alquil)n-hidróxiformami da n-(4 ' -substituìdos) como inibidores de metaloproteinase
HR20090009T HRP20090009T3 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors
CN2004800182447A CN1812974B (zh) 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{‘4-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物
NZ544208A NZ544208A (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyformamide compounds as metalloproteinase inhibitors
EP04743053A EP1644340B1 (en) 2003-06-27 2004-06-23 N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors
PT04743053T PT1644340E (pt) 2003-06-27 2004-06-23 Compostos de n-[({4¿-piperazina substituída-1-sulfonilmetil)alquil}]-n-hidroxiformamida como inibidores de metaloproteinases
DE602004017733T DE602004017733D1 (de) 2003-06-27 2004-06-23 N-Ä(ä4-SUBSTITUIERTEN PIPERAZIN-1-YLüSULFONYLMETHYL) ALKYLÜ -N-HYDROXYFORMAMIDE VERBINDUNGEN ALS METALLOPROTEINASE INHIBITOREN
ES04743053T ES2315675T3 (es) 2003-06-27 2004-06-23 Compuestos de n-(((4-sustituida piperazin-1-il)sulfonil-metil)alquil)-n-hidroxiformamida como inhibidores de metaloproteinasa.
CN201110103041XA CN102229589A (zh) 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{4′-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物
UAA200511723A UA81491C2 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors, pharmaceutical composition based thereon, proces for the preparation thereof, intermediate (variants)
PL04743053T PL1644340T3 (pl) 2003-06-27 2004-06-23 N-[({4-podstawione związki piperazyn-1-ylo}sulfonylometylo)alkilo]-n-hydroksyformamidowe jako inhibitory metaloproteinazy
RU2005141058/04A RU2351595C2 (ru) 2003-06-27 2004-06-23 N-гидроксиформамидные соединения в качестве ингибиторов металлопротеиназ
MXPA05013460A MXPA05013460A (es) 2003-06-27 2004-06-23 Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas.
US10/561,747 US7485644B2 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors
SI200430979T SI1644340T1 (sl) 2003-06-27 2004-06-23 N-(((4'-substituiran-piperazin-1-il)sulfonilmetil)alkil)-N- hidrioksiformamidne spojine kot metaloproteinazni inhibitorji
CA002529468A CA2529468A1 (en) 2003-06-27 2004-06-23 N-{[4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors
AT04743053T ATE414063T1 (de) 2003-06-27 2004-06-23 N-ä(ä4-substituierten piperazin-1- ylüsulfonylmethyl) alkylü -n-hydroxyformamide verbindungen als metalloproteinase inhibitoren
HK06106939.5A HK1086835B (en) 2003-06-27 2004-06-23 N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors
KR1020057024709A KR20060026440A (ko) 2003-06-27 2004-06-23 메탈로프로테이나제 억제제로서의 ｎ-[4-치환된피페라진-1-술포닐메틸알킬]-ｎ-히드록시포름아미드 화합물
DK04743053T DK1644340T3 (da) 2003-06-27 2004-06-23 N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer
TW093118692A TW200524898A (en) 2003-06-27 2004-06-25 Novel compounds
UY28387A UY28387A1 (es) 2003-06-27 2004-06-25 Compuestos novedosos
ARP040102258A AR044931A1 (es) 2003-06-27 2004-06-25 Compuestos de n-{'4-piperazina sustituida -1-sulfonilmetilalquil}-n-hidroxiformamidas como inhibidores de metaloproteasas
MYPI20042517A MY138680A (en) 2003-06-27 2004-06-25 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors
SA04250224A SA04250224B1 (ar) 2003-06-27 2004-07-14 مركبات من n -[(4`-بيبرازين مستبدل -1-يل}سيلفونيل ميثيل) الكيل]-n-هيدروكسي فورمايد باعتبارها مثبطات انزيمات البروتين المعدني
IL172615A IL172615A0 (en) 2003-06-27 2005-12-15 N-{4'-substituted piperazine -1-sulfonylmethyl-alkyl}-n- hydroxyformamide compounds as metalloproteinase inhibitors
ZA200510458A ZA200510458B (en) 2003-06-27 2005-12-22 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-N-hydroxyfomamide compounds are metalloproteinase inhibitors
CO05130352A CO5650254A2 (es) 2003-06-27 2005-12-27 Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa
IS8257A IS8257A (is) 2003-06-27 2006-01-23 N-{[4-útskipt píperasín-1-súlfónýlmetýl]alkýl}-N-hýdroxýfómamíðefnasambönd sem málmprótínkljúfstálmar
NO20060444A NO20060444L (no) 2003-06-27 2006-01-27 N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer
CY20091100064T CY1108757T1 (el) 2003-06-27 2009-01-19 Ενωσεις ν-{'4-υποκατεστημενη πιπεραζινη-1-σουλφονυλμεθυλαλκυλ}-ν-υδροξυφορμαμιδιου ως αναστολεις της μεταλλοπρωτεϊνασης.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
SE0301922D0 true SE0301922D0 (sv) 2003-06-27

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Country Status (33)

Country Link
US (1) US7485644B2 (https=)
EP (1) EP1644340B1 (https=)
JP (1) JP4701167B2 (https=)
KR (1) KR20060026440A (https=)
CN (2) CN102229589A (https=)
AR (1) AR044931A1 (https=)
AT (1) ATE414063T1 (https=)
AU (1) AU2004251104B2 (https=)
BR (1) BRPI0411929A (https=)
CA (1) CA2529468A1 (https=)
CO (1) CO5650254A2 (https=)
CY (1) CY1108757T1 (https=)
DE (1) DE602004017733D1 (https=)
DK (1) DK1644340T3 (https=)
ES (1) ES2315675T3 (https=)
HR (1) HRP20090009T3 (https=)
IL (1) IL172615A0 (https=)
IS (1) IS8257A (https=)
MX (1) MXPA05013460A (https=)
MY (1) MY138680A (https=)
NO (1) NO20060444L (https=)
NZ (1) NZ544208A (https=)
PL (1) PL1644340T3 (https=)
PT (1) PT1644340E (https=)
RU (1) RU2351595C2 (https=)
SA (1) SA04250224B1 (https=)
SE (1) SE0301922D0 (https=)
SI (1) SI1644340T1 (https=)
TW (1) TW200524898A (https=)
UA (1) UA81491C2 (https=)
UY (1) UY28387A1 (https=)
WO (1) WO2005000822A1 (https=)
ZA (1) ZA200510458B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
ZA200803327B (en) * 2005-10-26 2009-09-30 Serono Lab Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
DK2597084T3 (en) * 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
EP1187811B1 (en) * 1999-06-04 2007-03-07 AstraZeneca AB Inhibitors of metalloproteinases
PL365909A1 (en) * 2000-02-21 2005-01-10 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
MXPA04010555A (es) * 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
ATE411303T1 (de) * 2003-06-19 2008-10-15 Ucb Pharma Sa Hydroxamatsulfonamide als inhibitoren von cd23- shedding

Also Published As

Publication number Publication date
JP2007516164A (ja) 2007-06-21
JP4701167B2 (ja) 2011-06-15
ZA200510458B (en) 2007-03-28
TW200524898A (en) 2005-08-01
CY1108757T1 (el) 2014-04-09
MXPA05013460A (es) 2006-03-09
CN102229589A (zh) 2011-11-02
ES2315675T3 (es) 2009-04-01
CA2529468A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
US7485644B2 (en) 2009-02-03
UY28387A1 (es) 2005-01-31
HK1086835A1 (en) 2006-09-29
NO20060444L (no) 2006-03-22
US20070197542A1 (en) 2007-08-23
RU2351595C2 (ru) 2009-04-10
SI1644340T1 (sl) 2009-02-28
RU2005141058A (ru) 2006-07-27
EP1644340A1 (en) 2006-04-12
UA81491C2 (en) 2008-01-10
CN1812974B (zh) 2011-06-29
WO2005000822A1 (en) 2005-01-06
IS8257A (is) 2006-01-23
MY138680A (en) 2009-07-31
KR20060026440A (ko) 2006-03-23
EP1644340B1 (en) 2008-11-12
DE602004017733D1 (de) 2008-12-24
BRPI0411929A (pt) 2006-08-15
PL1644340T3 (pl) 2009-04-30
ATE414063T1 (de) 2008-11-15
CO5650254A2 (es) 2006-06-30
PT1644340E (pt) 2009-01-02
IL172615A0 (en) 2006-04-10
AU2004251104A1 (en) 2005-01-06
AR044931A1 (es) 2005-10-12
AU2004251104B2 (en) 2008-05-08
DK1644340T3 (da) 2009-02-02
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
HRP20090009T3 (en) 2009-02-28

Similar Documents

Publication Publication Date Title
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
AR036046A1 (es) Inhibidores de la hiv proteasa, composiciones que las contienen y sus usos farmaceuticos
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
EA200601235A1 (ru) Производные тиазола
PE20090042A1 (es) Analogos de ciclopamina
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
NO20001402L (no) Substituerte kromanderivater
CY1109085T1 (el) Νεα αλατα
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
ATE276257T1 (de) Pyrazinonderivate
ATE525366T1 (de) Benzoxazolderivate und pharmazeutische zubereitungen die diese enthalten
CY1108757T1 (el) Ενωσεις ν-{'4-υποκατεστημενη πιπεραζινη-1-σουλφονυλμεθυλαλκυλ}-ν-υδροξυφορμαμιδιου ως αναστολεις της μεταλλοπρωτεϊνασης.
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
ATE442354T1 (de) Pyrrolidinderivate als oxytocin antagonisten
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
EA200101204A1 (ru) Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции